BSH 2017 | Venetoclax: a lifesaving drug for CLL patients

Christopher Fox

Christopher Fox, MBChB, MRCP, FRCPath, from Nottingham University Hospital, Nottingham, UK discusses the success of venetoclax in treating patients with chronic lymphocytic leukemia (CLL) at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Up until recently, patients who failed or were intolerant to BCR inhibitor therapy, such as ibrutinib, had a dismal prognosis. However, results from the CLL forum data study have shown improved survival outcomes for patients on venetoclax who had previously failed other first-line therapy. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.

Share this video